Neuropsychological Functioning of Opiate-Dependent Patients: A Nonrandomized Comparison of Patients Preferring either Buprenorphine or Methadone Maintenance Treatment

REFERENCES

• European Monitoring Centre for Drugs and Drug Addiction. Office for Official Publications of the European Communities, Luxembourg 2006, Annual Report 2006: The State of the Drugs Problem in Europe
   Google Scholar
• Wechsberg W M, Kasten J J, Berkman N D, Roussel A E. Methadone Maintenance Treatment in the U.S.: A Practical Question and Answer Guide. Springer Publishing Co. Inc., U.S. 2007
   Google Scholar
• Mattick R P, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. 2003, Cochrane Database Sys Rev 2 CD002209
   Google Scholar
• Prosser J, Cohen L J, Steinfeld M, Eisenberg D, London E D, Galynker I I. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend 2006; 84: 240–247
   PubMed Web of Science ®Google Scholar
• Davis P E, Liddiard H, NcNillan T M. Neuropsychological deficits and opiate abuse. Drug Alcohol Depend 2002; 67: 105–108
   PubMed Web of Science ®Google Scholar
• Mintzer M Z, Copersino M L, Stitzer M L. Opioid abuse and cognitive performance. Drug Alcohol Depend 2005; 78: 225–230
   PubMed Web of Science ®Google Scholar
• Verdejo A, Toribio I, Orozco C, Lee Puente K L, Pérez-García M. Neuropsychological functioning in metadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend 2005; 78: 283–288
   PubMed Web of Science ®Google Scholar
• Curran H V, Kleckham J, Bearn J, Strang J, Wanigaratne S. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose response study. Psychopharmacology 2001; 154: 153–160
   PubMed Web of Science ®Google Scholar
• Tramullas M, Martínez-Cué C. Chronic methadone treatment and repeated withdrawal impair cognition and increase the expression of apoptosis-related proteins in mouse brain. Psychopharmacology 2007; 193: 107–120
   PubMed Web of Science ®Google Scholar
• Gossop M, Stewart D, Browne N, Mardsen J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effects of coping responses. Addiction 2002; 97: 1259–1267
   PubMed Web of Science ®Google Scholar
• Teichner G, Horner M D, Roitzsch J C, Herron J, Thevos A. Substance abuse treatment outcomes for cognitively impaired and intact outpatients. Addict Behav 2002; 27: 751–763
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson D R. Clinical efficacy of buprenorphine: Comparisons to methadone and placebo. Drug Alcohol Depend 2003; 70(Suppl. 2)49–57
   Web of Science ®Google Scholar
• Ponizovsky A M, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse 2007; 33: 631–642
   PubMed Web of Science ®Google Scholar
• Fiellin D, Pantalon M V, Pakes J P, O'Connor P G, Chawarski M, Schottenfeld R S. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002; 28: 231–241
   PubMed Web of Science ®Google Scholar
• Barnett P G, Rodgers J H, Bloch D A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001; 96: 683–690
   PubMed Web of Science ®Google Scholar
• Boothby L A, Doering P L. Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm 2007; 64: 266–272
   PubMed Web of Science ®Google Scholar
• Pickworth W B, Johnson R E, Holicky B A, Cone E J. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 1993; 53: 570–576
   PubMed Web of Science ®Google Scholar
• Stoller K B, Bigelow G E, Walsh S L, Strain E C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 2001; 154: 230–242
   PubMed Web of Science ®Google Scholar
• Strain E C, Stoller K, Walsh S L, Bigelow G E. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid-abusers. Psychopharmacology 2000; 148: 374–383
   PubMed Web of Science ®Google Scholar
• Mintzer M Z, Correia C J, Strain E C. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alcohol Depend 2004; 74: 205–209
   PubMed Web of Science ®Google Scholar
• Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: A naturalistic comparison of cognitive performance relative to healthy controls. BMC Clinical Pharmacology 2007; 7: 5
   PubMedGoogle Scholar
• Pirastu R, Fais R, Messina M, Bini V, Spiga S, Falconieri D, et al. Impaired decision-making in opiate-dependent subjects: Effect of pharmacological therapies. Drug Alcohol Depend 2006; 83: 163–168
   PubMed Web of Science ®Google Scholar
• Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients. J Clin Psychopharmacol 2005; 25: 490–493
   PubMed Web of Science ®Google Scholar
• Hautzinger M, Bailer M. Allgemeine Depressivitätsskala (ADS). Die deutsche Version des CES-D [General depression scale. The german version of the CES-D]. Beltz, Weinheim 1991
   Google Scholar
• DiFrancesco R, Fischl M A, Donnelly J, Zingman B S, McCance-Katz E F, Moody D E, et al. Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. J Pharm Biomed Anal 2007; 44: 188–195
   PubMed Web of Science ®Google Scholar
• Lugo R A, Satterfield K L, Kern S E. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005; 19: 13–24
   PubMedGoogle Scholar
• Cohen R A. Neuropsychology of Attention. Plenum, New York 1994
   Google Scholar
• Posner M I, Boies S J. Components of attention. Psychol Rev 1971; 78: 391–408
   Web of Science ®Google Scholar
• Schuhfried G. Wiener Test-System. Psychologial diagnostics [Wiener Testsystem. Psychologische Diagnostik]. Katalog. 2005
   Google Scholar
• Brickenkamp R. d2 Attention-Strain Test [Aufmerksamkeits-Belastungstest]. Hogrefe, Göttingen 2002
   Google Scholar
• Reitan R M. Trail Making Test. Manual for Administration and Scoring. Reitan Neuropsychology Laboratory, Tucson (AZ) 1992
   Google Scholar
• Delis D C, Kramer J, Kaplan E, Ober B A. California Verbal Learning Test (CVLT) Manual. Psychological Corporation, San Antonio (TX) 1987
   Google Scholar
• Schmidt K-H, Metzler P. Vocabulary test [Wortschatztest (WST)]. Beltz Test GmbH, Weinheim 1992
   Google Scholar
• Hermann D, Klages E, Welzel H, Mann K, Croissant B. Low efficacy of non-opioid drugs in opioid withdrawal symptoms. Addict Biol 2005; 10: 165–169
   PubMed Web of Science ®Google Scholar